Browse the evidence

GLP-1 receptor agonists (specifically liraglutide) exert direct anti-inflammatory and chondroprotective effects in osteoarthritis by suppressing NF-κB activation, reducing pro-inflammatory cytokines (IL-1β, IL-6, TNF-α), and downregulating cartilage-degrading enzymes (MMPs, ADAMTS), while promoting type II collagen synthesis.

Research shows that GLP-1 drugs may protect knee cartilage directly by reducing inflammation and stopping enzymes that break down joint tissue, in addition to helping you lose weight. This suggests these drugs might slow the progression of osteoarthritis, not just mask the pain.

GLP-1 receptor agonists reduce the incidence of knee surgeries and slow cartilage loss in patients with knee osteoarthritis and type 2 diabetes, as demonstrated in real-world observational cohorts.

For patients with knee OA and diabetes, using GLP-1 drugs like liraglutide or semaglutide is associated with a lower risk of needing knee surgery and slower loss of knee cartilage compared to not using these drugs. This suggests they may help preserve joint structure over time.

The gut microbiota causally influences obesity and metabolic disorders by modulating the secretion of gut hormones (GLP-1, ghrelin, PYY) and influencing hypothalamic neuroendocrine pathways, suggesting microbiota-based therapies as a potential treatment.

While microbiota-based therapies are still being researched, the gut microbiome plays a role in regulating appetite hormones like GLP-1 and ghrelin. Dietary patterns that support a healthy microbiome may contribute to better metabolic health and weight management.

GLP-1 receptor agonists (specifically Exendin-4, Liraglutide, and native GLP-1) modulate human mesenchymal stem cell (hMSC) function by promoting osteogenesis and inhibiting adipogenesis through context-, dose-, and timing-dependent mechanisms.

GLP-1 medications (like Ozempic or Trulicity) are primarily used for diabetes and weight loss, but research suggests they also interact with your body's stem cells. Specifically, they appear to encourage bone-forming cells to work better while discouraging fat-storing cells from differentiating. This effect depends heavily on the specific drug, the dose, and the timing of exposure. While this is promising for regenerative medicine, it is currently based on lab studies, not human clinical trials for tissue repair.

Ghrelin, the only gastrointestinal hormone that increases appetite, stimulates dopamine release in the VTA to increase food motivation and sex motivation in males, but reduces sex motivation in females during lactation.

Ghrelin increases hunger and food motivation by stimulating dopamine release in the brain. In males, it may also increase sex motivation, while in lactating females, it may reduce sex motivation to prioritize maternal care. Understanding these hormonal signals can help manage hunger and motivated behaviors.

During the stable weight maintenance phase, the appetite-suppressing effects of GLP-1 medications may diminish for some patients, leading to a gradual return of hunger, cravings, and food noise, though often less intense than pre-treatment levels.

If you are on long-term GLP-1 medication and notice your hunger or cravings returning slightly, this is a known phenomenon called the 'stable phase' transition. It does not necessarily mean the drug has failed. You may need to adjust your eating habits or discuss dose adjustments with your doctor. The return of hunger is often less severe than before treatment.

Combination therapy using atomoxetine and oxybutynin reduces OSA severity by approximately 60% by activating pharyngeal dilator muscles.

This combination drug is currently in clinical trials (Phase III) and not yet widely available. It targets the muscle function aspect of sleep apnea. If you are not a candidate for CPAP or weight loss drugs, you may want to ask your doctor about upcoming clinical trials for this specific combination.

Carbonic anhydrase inhibitors such as acetazolamide reduce OSA severity by 40-50% in patients with high loop gain.

If you have high loop gain OSA, ask your doctor about carbonic anhydrase inhibitors like acetazolamide. These can reduce your apnea severity by 40-50% by stabilizing your breathing control. Be aware of potential side effects like tingling or stomach upset.

Brown adipose tissue (BAT) activation and white-to-brown adipose tissue transformation reduce obesity risk by increasing energy expenditure and improving glucose homeostasis.

Focus on strategies that may support metabolic health and energy expenditure, such as exposure to cold or specific dietary patterns, as these may influence brown fat activity. However, consult a healthcare provider for personalized advice, as this is a complex physiological area.

Leptin resistance, caused by impaired blood-brain barrier transport or receptor signaling defects, prevents the hormone from suppressing appetite and regulating body weight in obese individuals.

Understanding leptin resistance highlights why simple calorie counting might fail. It suggests that metabolic health, including blood-brain barrier integrity and receptor sensitivity, is crucial. Work with a healthcare provider to address underlying metabolic health.

GLP-1 receptor agonists (semaglutide and liraglutide) are primarily requested by the public for off-label cosmetic weight loss, often without prescriptions or medical advice, creating a high risk of misuse and safety concerns.

GLP-1 medications like semaglutide and liraglutide are powerful tools for weight management and diabetes, but they are not cosmetic shortcuts. Most requests for these drugs are for weight loss without a prescription, which poses safety risks. If you are considering these medications, consult a healthcare provider to ensure they are appropriate for your health needs and to receive proper guidance on usage and side effects.

GLP-1 receptor agonists and dual incretin therapies (semaglutide, liraglutide, tirzepatide) do not show a disproportional reporting signal for suicidal ideation or suicide attempt compared to non-GLP-1 anti-obesity drugs.

Current pharmacovigilance data does not support a causal link between GLP-1 or dual incretin weight-loss drugs and suicidal ideation or attempts. While patients should be monitored as standard practice, the absolute risk appears neutral compared to other anti-obesity medications.

Non-GLP-1 anti-obesity drugs, specifically naltrexone/bupropion, show elevated disproportional reporting signals for suicidal ideation and suicide attempt compared to GLP-1/dual incretin therapies.

Naltrexone/bupropion shows a higher reporting signal for suicidality compared to GLP-1 drugs, which is consistent with its known pharmacology. Patients using this medication should be monitored for mood changes.

Modifying structural and social determinants of health (SDOH), such as housing and economic stability, is a necessary lever for achieving health equity in obesity treatment, as individual-level interventions alone fail to address root causes of disparities.

To improve obesity outcomes for marginalized groups, interventions must go beyond diet and exercise advice. They need to address structural barriers like housing stability and income. Policy changes and community-level investments are essential to create equitable opportunities for health.

Specific fatty acid esters of hydroxy fatty acids (FAHFAs), particularly 5-PAHSA and 9-PAHSA, improve insulin sensitivity and glucose-stimulated insulin secretion.

Research shows that specific fatty acid derivatives called FAHFAs (like 5-PAHSA) can improve how your body handles insulin and glucose. However, this is currently based on animal studies and human observational data, not proven clinical treatments. Do not self-prescribe specific isomers until more clinical trials are available.

Duodenal Mucosal Resurfacing (DMR) significantly improves glycaemic control in Type 2 Diabetes patients by enhancing insulin sensitivity.

Duodenal Mucosal Resurfacing (DMR) is a new, minimally invasive procedure that can help lower blood sugar in Type 2 Diabetes. It works by treating the duodenum to improve insulin sensitivity. Clinical trials show it reduces HbA1c levels, and the more duodenum treated, the better the result. It is a safe option for those who may not respond well to standard treatments.

Tirzepatide can cause rare, idiosyncratic hepatocellular injury presenting as asymptomatic or symptomatic aminotransferase elevation, which resolves upon drug discontinuation.

If you are taking tirzepatide and develop persistent abdominal pain, nausea, or dark urine, do not assume it is just a standard side effect. Request liver enzyme testing (ALT/AST) immediately. If elevated, stopping the medication typically resolves the injury, but early detection prevents severe liver damage.

Tirzepatide use is associated with a high frequency of early-onset adverse events, with a median time-to-onset of approximately 6.4 days, driven by gastrointestinal disturbances, injection site reactions, and metabolic effects.

If you start tirzepatide, expect side effects like nausea or injection site pain to happen quickly, often within the first week. This is common and usually transient, but you should monitor yourself closely during the initial days of treatment.

Tirzepatide use is associated with specific adverse events in females, including starvation ketoacidosis, menstrual disorders, and postmenopausal hemorrhage.

Women taking tirzepatide should be aware of potential changes in their menstrual cycle, including irregular bleeding or postmenopausal hemorrhage. If you experience these changes, consult your healthcare provider.

Tirzepatide use is associated with specific adverse events in males, including sleep disorders, delayed gastric emptying, and medullary thyroid cancer.

Men taking tirzepatide should be aware of potential sleep issues and digestive delays. Those with a family history of thyroid cancer should discuss the risks with their doctor before starting treatment.

Off-label use of GLP-1 receptor agonists (specifically semaglutide) for weight loss can precipitate euglycemic starvation ketoacidosis in non-diabetic individuals, primarily through gastrointestinal side effects causing reduced oral intake and starvation.

If you are using GLP-1 medications like semaglutide for weight loss, do not source them from unregulated online pharmacies. The risk of receiving counterfeit or improperly dosed products is real and can lead to severe metabolic issues. If you experience persistent nausea, vomiting, or inability to eat, seek medical attention immediately, as this can lead to euglycemic ketoacidosis—a dangerous condition where your blood becomes acidic despite normal blood sugar levels. Never ignore severe gastrointestinal side effects.

Systemic administration of the GIP receptor agonist DA-GIP suppresses inflammation-induced conditioned taste avoidance (CTA) and reduces parabrachial CGRP neuron activation, acting via distinct neural circuits than its anorectic effects.

For individuals experiencing severe nausea or food aversion due to inflammation (e.g., chronic autoimmune conditions or post-infection), standard anti-nausea medications (like ondansetron) or anti-inflammatories (NSAIDs) may not fully resolve the aversion. Emerging GIP-based therapies show promise in specifically targeting the neural circuits responsible for this aversion without necessarily worsening appetite suppression, potentially improving quality of life during inflammatory episodes.

GIP receptor agonism enhances inflammation-induced anorexia via the Dorsal Vagal Complex (DVC), while its anti-aversive effects are mediated by parabrachial CGRP neurons, demonstrating that food intake suppression and aversion are dissociable.

Current understanding of GLP-1/GIP drugs often focuses on weight loss. This research suggests these drugs also have a distinct, potent anti-nausea/anti-aversion effect mediated by different brain circuits. This dual-action profile could be leveraged to manage quality of life in patients with chronic inflammatory conditions who suffer from both weight loss and severe food aversion.

Low-dose semaglutide (30 nmol/kg twice weekly) attenuates pathological cardiac and hepatic remodeling and improves exercise capacity in a rodent model of HFpEF independently of weight loss.

This preclinical study suggests that low-dose GLP-1 therapy may offer direct heart and liver protection in heart failure with preserved ejection fraction (HFpEF) without requiring weight loss. While promising, this is animal data; human application requires clinical validation.